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Graft-versus-host  disease  (GVHD)  1 is  still  the  most  important  barrier  to 
successful allogeneic bone marrow (BM) transplantation in man and in labora- 
tory animals  (1-3).  GVHD is especially severe when donor and recipient are 
completely allogeneic, and differ at the major histocompatibility genetic region 
(4,  5).  Several investigators have been able to reduce or eliminate GVHD by 
depleting the BM inoculum of T cells or T-cell precursors (6-8), or by treating 
the  adoptive  recipients  with  potent  immunosuppressive  drugs  for  at  least 
several months after marrow transplantation (1, 2). 
We recently reported that preparation of allogeneic marrow recipients with 
high-dose,  fractionated,  total  lymphoid irradiation  (TLI)  allows  for  marrow 
engraftment and stable  chimerism in rats  and mice without development of 
clinical GVHD (9).  2 TLI is a relatively safe form of radiotherapy, routinely used 
to treat lymphoid malignancies in man (10). Two critical features of TLI used in 
animals and man are the shielding of radiosensitive nonlymphoid organs (e.g., 
long bones, lungs, kidneys, skull) with lead, and the high dose of irradiation 
(3-4  ×  103 rads) achieved by multiple small fractions of 2-2.5  ×  102 rads each. 
In the present work, we compared the outcome of allogeneic BM transplanta- 
tion in BALB/c mice treated with TLI, lethal whole-body irradiation (WBI), or 
fractionated  thymic irradiation.  Marrow  donors  were  completely allogeneic 
(C57BL/Ka),  and differed from the hosts at the H.2 region. The experimental 
results showed that recipients prepared with WBI developed a virulent GVHD 
such that the majority of animals were dead within 3 wk. On the other hand, 
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recipients  prepared  with  TL!  showed  no  clinical  signs  of  GVHD,  and  85% 
survived  longer  than  250  days.  The  surviving animals  were  stable  chimeras. 
Recipients given thymic irradiation showed no evidence of marrow engraftment. 
Materials  and  Methods 
Animals.  Inbred BALB/c (H-2  d/d) mice, 4-6 mo old, were used as recipients for skin and BM 
allografts. Inbred C57BL/Ka (H-2b/b), 1-4 mo old, were the donors of BM and skin grafts. All mice 
were bred in pathogen-free conditions in the Division of Radiobiology, Department of Radiology, 
Stanford University, but they were transferred to conventional housing before use in irradiation 
experiments. At the onset of irradiation, a broad-spectrum antibiotic (tetracycline hydrochloride; 
American Cyanamid Co., Princeton, N. J.) was added to the drinking water. 
Radiation  Source.  A  Philips unit  (250  kV,  15 mA;  Philips Medical Systems  Inc.,  Shelton, 
Conn.) delivered x-rays at a  rate of 59 rad/min. The source-to-skin distance was 60 cm. 0.25-mm 
Cu  and  1.0-ram  A1  correction  filters  were  used  and  the  dosimetry  was  determined  using  a 
calibrating ionizing chamber and lithium fluoride thermoluminescence dosimeters. 
Irradiation Procedure.  The irradiation procedure was previously described in detail  (9,  11, 
12). Anesthetized BALB/c mice were positioned in a lead apparatus, exposing the major lymphoid 
organs, including the thymus and the spleen with proper shielding of the skull, lungs, ribs, hind 
legs, and tail. In some experiments, the thymus was shielded by placing a piece of lead (0.5 x 0.5 
cm) over the mediastinum. Thymic irradiation alone was accomplished by exposing the medias- 
tinum, and shielding the rest of the body with lead. Irradiation protocols consisted of fractions of 
200 rads/day, five times a week, to achieve a total dose of 3,400 rads (unless specified otherwise in 
the text). WBI was delivered using the same radiation source to administer a single dose of 1,000 
rads. 
BM Transplantation.  The BM cells were flushed out of isolated long bones (femur~ tibia, and 
humerus) using a 25-gauge needle, and minimal essential medium (MEM). The cells were washed 
once,  filtered  through  a  nylon  mesh,  and  resuspended  in  MEM.  0.25-ml  aliquots  of medium 
containing 10 ×  106 or 30  ×  106 nucleated cells were injected into the lateral tail vein of recipient 
mice. 
Skin Transplantation.  Full-thickness C57BL/Ka skin obtained from the abdomen of 4- to 6- 
wk-old  female  mice  were  transplanted  to  the  flank  of  BALB/c  recipients  (13).  Grafts  were 
considered rejected at the time of complete sloughing, or when a  dry scab was formed. 
Purification of Peripheral Blood Lymphocytes (PBL).  Blood obtained from the retro-orbital 
veins was placed in preservative-free heparin coated glass tubes.  Samples were diluted (1:5)  in 
phosphate-buffered saline  (PBS),  and the PBL  were purified  using a  Ficoll-Hypaque  gradient 
(14).  Contaminating erythrocytes were lysed with ammonium chloride (15). 
Assay for Chimerism.  Chimerism of the PBL of BM recipients was assayed using a  comple- 
ment-dependent microcytoxicity assay with a specific anti-H-2  b alloantiserum (B10.A(5R) × A)F1 
anti-B10.A(2R)  (kindly  supplied  by  Dr.  D.  B.  Murphy,  Department of  Medicine,  Stanford 
University) as described previously (13).  Purified PBL were suspended in medium 199 (Microbio- 
logical Associates, Inc., Bethesda, Md.) containing 5% heat-inactivated fetal calf serum (2  ×  106 
cells/ml).  10 ~1 of the lymphocyte suspension was incubated with 10 ~1 of anti-H-2  b antiserum 
(1:10)  for 30 min at room temperature in 6 x 50-mm glass tubes (Kimble Products,  Div. Owens- 
Illinois, Inc., Toledo, Ohio). 5 ftl of guinea pig complement was added for an additional 45 min at 
room temperature.  The cells were spun at 250 g  for 5 rain, and resuspended in 15 ~l of medium 
199.  15 pl of a  0.1% solution of trypan blue was added before examining the viability of cells in a 
standard  hemocytometer.  The  cytotoxicity  index  was  calculated  by comparing  the  number of 
viable cells present after treatment with anti-H-2  b antiserum to that after treatment with normal 
mouse serum. Negative (BALB/c; PBL ---5% cytotoxicity) and positive (C57BL/Ka; PBL, 95-100% 
cytotoxicity)  controls  were  performed  in  each  experiment.  Cytotoxicity  assays  were  done  in 
triplicate, and read'by a blind observer. Data shown in tables _(percent of donor |H-2  b] type cells) 
is the mean _+ SD of triplicate values of the cytotoxicity index. 
Results 
Effect of TLI on Allogeneic Skin and Marrow Survival.  Adult BALB/c mice 
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TABLE  I 
Survival of C57BL/Ka BM and Skin Allografts  in BALB/c Mice Treated with Different 
Radiation Protocols 
Number of 
Recipient treat-  C57BL/Ka Number 
ment  BM cells in-  of mice 
jected 
C57BL/Ka skin graft  Fraction  Percent of donor-type 
survival  of mice  cells in PBL of recipi- 
with long-  ents* 
term skin 
graft  sur- Skin graft  Skin graft 
vival 
Mean  Range  (>I00  >I00 days <i00 days 
survival  survival 
days) 
rads  days 
TLI, 3,400  0  16  49.1  35-67  0/16  -  - 
TLI, 3,400  10 × 106  15  >2505  8/15  44  0 
TLI, 3,400  30 × 106  27  >100§  24/27  91  37 
TLI, 1,400  0  7  18.4  13-27  0/7 
TLI, 1,400  30 × 106  11  17.{~  I  13-2~  t  1/11  ND  0 
TLI, 3,400 with  0  10  18.0  16-25  0/10  -  - 
thymus shield 
Thymus only  0  4  15.7  15-16  0/4  -  - 
3,400 
Thymus only  30 × 106  6  16.3  14-18  0/6  -  0 
3,400 
None  0  12  10.7  10-13  0112  -  - 
* Chimerism was determined in pooled blood samples obtained 7,100 days after BM transplanta- 
tion. Representative  results  of one of four experiments are shown. 
5 Data shown is mean of 8/15 mice with  long-term skin  grafts.  In 7/15 mice, C57BL/Ka skin 
survival  was 34-90 days. 
§ Data shown is mean of 24/27 mice with  long-term skin grafts.  In 3/27 mice, C57BL/Ka skin 
survival  was ~ 20 days. 
ii  Data shown is mean and range of  10/11  mice with skin survival  _< 24 days. 
ND, not done. 
(3,400  rads)  prolonged the  survival  of C57BL/Ka skin  aUografts  (mean,  49.1 
days)  about five times  as  comparecl to  that  (mean  ,  10.7  days) on untreated, 
control BALB/c recipients  (Table I).  8 of 15 recipients treated  with TLI (3,400 
rads)  and given  10  x  106 C57BL/Ka BM cells  intravenously,  maintained skin 
allografts for longer than 100 days (Table I). Increasing the dose of BM cells to 
30  x  l0  s resulted  in  long-term  (>100 days) skin allograft survival in 24 of 27 
recipients. 
Typing  of  the  histocompatibility  antigens  (H-2)  of  the  peripheral  blood 
lymphocytes of BALB/c mice bearing long-term C57BL/Ka skin grafts showed 
that these animals were stable chimeras (Table I). The level of chimerism was 
related to the dose of BM cells injected (Table I). 
Effect of Dose of Irradiation on Allogeneic Skin and BM Graft Survival.  To 
determine  the  effect of the  dose  of irradiation  on  skin  and  marrow  allograft 
survival,  several BALB/c mice were given TLI with a  total dose of 1,400 rads. 
Skin  graft survival  was  slightly prolonged  (mean,  18.4  days)  as  compared to 
controls (Table I).  1 of 11  mice given TLI (1,400 rads) and 30  x  106 C57BL/Ka 
BM  cells  maintained  a  C57BL/Ka  skin  graft  for  longer than  100  days.  The 
remaining 10 mice rejected their grafts by day 24,  and showed no evidence of 
chimerism  100  days  after  BM  transplantation  (Table  I).  This  indicates  that 966  TRANSPLANTATION  OF  ALLOGENEIC  BONE  MARROW 
uniform long-term BM graft survival is critically dependent upon the dose of 
irradiation exceeding 1400 rads. 
Effect  of  Thymic  Irradiation  on  Allogeneic  Skin  and  BM  Graft 
Survival.  Table I  shows that C57BL/Ka skin grafts placed on BALB/c mice 
given TLI (3,400 rads) with thymic shielding survived for a much shorter period 
of time (mean, 18.0 days) than did grafts placed on recipients given TL! (3,400 
rads)  without  thymic  shielding  (mean,  49.1  days).  This  suggests  that  the 
thymus plays an important role in the chronic immunosuppression induced by 
TLI.  To examine the immunosuppression induced by high dose,  fractionated 
irradiation of the thymus alone, several BALB/c mice received 3,400 rads (200- 
rad fractions) to the thymus with shielding of all other tissues. The survival of 
skin  allografts  placed  on  the  latter  recipients  was  only  slightly  prolonged 
(mean,  15.7 days) as compared to unirradiated controls (Table I).  Mice given 
thymic irradiation  and 30  ×  106  allogeneic BM  cells  showed no  evidence of 
chimerism after 100 days. Skin grafts transplanted on the day after the injection 
of the allogeneic BM survived no more than 18 days (Table I). This shows that 
both the thymus and the peripheral lymphoid tissues must be included in the 
irradiation fields in order to achieve the full immunosuppressive effects of TLI. 
GVHD after BM Transplantation in Mice Given WBI.  Fig. 1 A shows that a 
single dose of 1,000 rads of WBI killed 100% of BALB/c mice within 11 days. All 
mice given WBI could be rescued by a  single intravenous injection of 30  ×  106 
syngeneic BM cells on the day after irradiation (Fig.  1 A). Although 30  ×  106 
allogeneic BM cells prolonged the lives of BALB/c mice given WBI, the majority 
of recipients died by day  12,  and 95%  died by  day 61  (Fig.  1 A).  The  latter 
recipients showed typical changes of GVHD,  including weight loss,  hunched 
back, diarrhea, and alopecia, and skin erythema. 
Lack of GVHD after BM Transplantation in Mice Given TLI.  Fig. 1 B shows 
that TLI (3,400  rads) alone is not a  lethal form of radiotherapy, since 90%  of 
irradiated mice survive longer than 100 days, and over 80% survive longer than 
250  days.  However,  we have observed considerably higher mortality figures 
during periods of known intercurrent infection in our mouse holding rooms. We 
therefore chose to  present  mortality data  of mice given  either  WBI  or TLI 
during a period of time when there was no obvious infection of animals in our 
holding facility. 
Transplantation  of allogeneic  BM  cells  (30  ×  106) slightly  increased the 
mortality of BALB/c mice given TLI. However, 80% of marrow recipients sur- 
vived longer than  110  days.  None  of the marrow  recipients  showed clinical 
evidence of GVHD  (diarrhea, hunched back, ruffled fur). Although recipients 
sometimes lost 20-35%  of their body weight during the irradiation treatment, 
animals gained weight after BM transplantation. The majority of recipients re- 
gained their pretreatment weight within 4-6 wk. None of the long-term survivors 
showed clinical evidence of GVHD. The cause of death of the 15% of animals is 
unclear,  since none of these  BM  recipients  showed obvious  signs  of GVHD. 
Autopsy specimens frequently showed evidence of pneumonitis and enteritis, 
without splenomegaly. We have observed similar autopsy findings in untreated 
control mice that have succumbed during residence in the same animal rooms 
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FIG.  1.  Survival of BALB/c mice given either TLI, 3,400 rads, or WBI, 1,000 rads, and 30 
x  106 C57BL/Ka BM cells. (A) Survival of 8 mice given WBI and no BM cells, 26 mice given 
WBI and 30  x  106 C57BL/Ka BM cells,  and 8  mice given  WBI and 30  x  10  e BALB/c BM 
cells.  BM cells were injected intravenously  i  day after WBI.  (B) Survival of 146 mice given 
TLI and no BM cells, and 71 mice given TLI and 30  ×  106 C57BL/Ka BM cells.  The latter 
group of mice were set up later than the former,  and survival is shown up to the present 
time.  r, rads. 
GVHD after the Transfer of Allogeneic Spleen Cells to Mice Given  WBI or 
TLI.  Fig. 2 shows that BALB/c recipients given WBI (1,000 rads) and ~0 ×  106 
C57BL/Ka spleen cells intravenously,  all died within  10 days after irradiation 
and  cell  transfer.  In  addition,  all  mice  given  TLI  (3,400  rads)  and  30  x  106 
allogeneic spleen cells succumbed by day 46 (Fig. 2). Both groups of mice showed 
signs of vigorous GVHD.  These findings  show that spleen cells induce a  more 
rapid GVHD than do BM cells in mice given WBI, and that mice given TLI are 
protected against clinical GVHD by allogeneic BM,  but not by spleen cells. 
To  determine  whether  or  not  allogeneic  spleen  cells  can  induce  GVHD  in 
stable  chimeras,  several  BALB/c  mice  given  TLI  (3,400  rads)  and  30  ×  106 
C57BL/Ka BM cells were injected with C57BL/Ka spleen cells after chimerism 
had  been  documented.  Fig.  2  shows  the  survival  of C57BL/Ka  ~  BALB/c 
chimeras  given  intravenous injections  of 30  x  106 spleen cells  on days 78,  92, 
106,  118,  150,  and  160  after  BM  transplantation.  All  animals  in  the  group 
survived  at  least  90  days  after  the  last  spleen  cell  injection,  and  showed  no 968  TRANSPLANTATION  OF  ALLOGENEIC  BONE  MARROW 
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FIG.  2.  Survival of BALB/c mice given either TLI (3,400 rads) or WBI (1,000 rads) and 30 
×  106 C57BL/Ka spleen cells. Results from four groups of mice are shown. The first group 
(14 mice) was given WBI, and a single intravenous injection of spleen cells 1 day later. The 
second group (6 mice) was given TLI and a single intravenous injection of spleen cells 1 day 
after the completion of TLI. The third group (4 mice) was given TLI, and six intravenous 
injections of spleen cells on days 180,  194, 220, 240, 268, and 280 after the completion of TLI 
(indicated by arrows).  The fourth group (6 mice) was given TLI, and 30  ×  106 C57BL/Ka 
BM  cells  1  day  after  the  completion  of TLI.  In  addition,  these  animals  received  six 
intravenous  injections of spleen  cells  on  days  78,  92,  106,  118,  150,  and  160  after  the 
completion of TLI. The latter recipients were all shown to be stable chimeras before spleen 
cell injections were begun, r, rads. 
evidence  of GVHD.  This  shows  that  C57BL/Ka  spleen  cells  cannot  induce 
GVHD in C57BL/Ka --* BALB/c chimeras despite the fact that the chimeras are 
specifically  tolerant  to  C57BL/Ka  transplantation  antigens  (9).  In  control 
experiments,  BALB/c  mice given TLI  without  BM  cells received C57BL/Ka 
spleen cell injections more than 100 days after irradiation.  None of the latter 
animals  developed GVHD.  However, our previous experiments indicate that 
the latter recipients recover their ability to respond to allogeneic lymphocytes 
in  vitro by  100  days  (9).  3 Therefore, it  is  likely that these mice rejected the 
allogeneic spleen cells. 
Effect of Presensitization  on BM and Skin Allograft Survival in Mice Given 
TLI.  A  significant problem in clinical organ and BM transplantation is the 
presensitization  of prospective  recipients  with  blood  products  which  share 
transplantation antigens with donor tissues (1). We therefore sensitized normal 
BALB/c mice with two 0.25-ml intravenous injections of C57BL/Ka  blood,  18 
and 11 days before initiating TLI. The latter recipients received 30 × 106 C57BL/ 
Ka BM cells and a skin allograft at the end of TLI. Table II shows that all skin 
grafts  were  rejected after  24  days.  None  of these  mice  showed evidence of 
chimerism of the peripheral  blood lymphocytes 100  days after BM  and skin 
transplantation.  Thus,  presensitization  with  peripheral  blood  prevented the 
3 S. Slavin, S. Nimelstein, and S. Strober. Specific humoral transplantation tolerance to H-2 
antigens in mice treated with total lymphoid irradiation. Manuscript in preparation. S.  SLAVIN,  Z.  FUKS,  H.  S.  KAPLAN,  AND  S.  STROBER 
TABLE  II 
Effect of Presensitization of BALB/c Mice with Donor-Type Blood on the 
Long-Term Survival of C57BL/Ka BM and Skin Allografts after TLI* 
969 
Fraction of  recipi- 
Presensitization  Donor-type cells  Mean C57BL/Ka skin  ents with long-term 
protocol  in PBL  allograft  survival  (>100 days) skin 
graft  survival 
%  days 
0  91~  >100§  24/27 
C57BL]Ka Blood  0 ~  18.7 (range 17-24)  0/8 
0.25 ml days 
-18,  -11 
* Experiments involved 30  ×  10  ~ C57BL/Ka BM cells, and TLI with 3,400 rads. 
Chimerism was determined in pooled blood sample in mice with long-term skin 
grafts. 
§ The data shown is the mean of 24/27 mice with long-term skin grafts. 
i~ Chimerism was determined on pooled blood sample obtained >100 days after skin 
and marrow transplantation, 
TABLE  III 
Effect of Presensitization of BALB/c Mice with Donor-Type Skin on 
C57BL/Ka Skin Allograft Survival after TLI* 
Number of 
Presensitization  Irradiation 
mice 
C57BL/Ka Skin 
Mean  Range 
days 
None  None  12  10.7  10-13 
None  TLI  12  49.1  35-67 
C57BL/Ka skin graft*  TLI  6  23.0  20-27 
C57BL/Ka skin graft§  None  4  8.2  7-12 
* TLI carried out with 3,400 rads. 
$ Presensitizing allograR placed 24 days before TLI.  Final graft placed 1 day after 
TLI. 
§ Presensitizing allograft placed 6 mo before final C57BL/Ka skin graft. 
establishment of stable chimerism observed after TLI and BM transplantation 
in unsensitized hosts (Table II). 
The effect of presensitization of recipients was further studied by immunizing 
several BALB/c mice with C57BL/Ka skin grafts 24 days before the initiation of 
TLI. At the end of TLI, all mice received a second skin allograft. Table III shows 
that presensitization markedly reduced the survival of the skin allografts (mean 
survival, 23 days) as compared to that observed with unsensitized hosts (mean 
survival,  49.1 days).  However, graft survival was still twice as long as that of 
grafts placed on unirradiated,  unsensitized  BALB/c mice  (Table I),  and three 
times as long as that on unirradiated,  presensitized recipients  (Table III). 
Discussion 
The object of the present work was to further investigate the  use of TLI in 
allogeneic BM transplantation.  Our previous studies showed that BALB/c mice 
given TLI  (3,400  rads)  accepted C57BL/Ka BM without clinical  GVHD.  How- 970  TRANSPLANTATION  OF  ALLOGENEIC  BONE  MARROW 
ever, long-term BM engraftment occurred in only 53% of recipients given 10  x 
106 cells, and the vigor of GVHD in this strain  combination was not tested in 
recipients prepared with lethal WBI. 
The present investigation shows that increasing the dose of injected BM cells 
from 10  x  106 to 30  x  106 increased the percentage of recipients with long-term 
(>100 days) BM grafts from 53 to at least 90%.  The percentage of donor-type 
lymphocytes in  the  blood also  increased  from  44 to  91%.  All of the  chimeric 
animals  maintained  skin  allografts  for  more  than  100  days,  and  showed no 
clinical signs of GVHD (hunched back, weight loss, diarrhea,  etc.). 
Reduction of the cumulative dose of TLI to 1,400 rads substantially reduced 
the nonspecific immunosuppressive effects observed with 3,400 rads, since skin 
allograft  survival  with the  low dose  (mean,  18.4  days) was considerably less 
than  that with the high dose (mean,  49.1  days).  Reduction of the dose of TLI 
also decreased the frequency of recipients with long-term BM engraftment  to 
<10% after the injection of 30  x  106 BM cells. 
The critical importance of irradiation  of the thymus during TLI was demon- 
strated  by  the  marked  decrease  in  the  survival  of C57BL/Ka  skin  grafts 
transplanted to recipients given TLI with thymic shielding as compared to that 
in recipients given TLI with the thymus exposed. However, fractionated, high- 
dose irradiation (3,400 rads total, 200 rads/fraction) of the thymus alone resulted 
in only marginal prolongation  of skin graft survival  (mean survival,  18 days). 
None of the recipients  given thymic irradiation  alone accepted long-term BM 
grafts.  These findings suggest that irradiation  of both the thymus and periph- 
eral lymphoid tissues is necessary to achieve the full immunosuppressive effects 
of TLI. 
To  study  the  vigor  of  the  GVHD  in  the  C57BL/Ka  --*  BALB/c  strain 
combination,  BALB/c mice were given a  single lethal dose (1,000 rads) of WBI 
and  30  x  106  C57BL/Ka  BM cells.  The  majority of recipients  died  within  12 
days,  and  95%  died  within  61  days.  All irradiated  recipients  given  30  x  106 
syngeneic BM cells survived longer than 250 days. Allogeneic marrow recipients 
showed typical signs of GVHD with alopecia,  weight loss, hunched  back,  and 
diarrhea.  In  contrast,  >80%  of mice  given  TLI  alone,  or TLI  and  30  x  106 
allogeneic  BM  cells  survived  at  least  110  days  after  BM  transplantation. 
Although the marrow recipients were chimeric,  none showed clinical  signs of 
GVHD. The cause of death of those animals which died in these latter groups is 
not clear.  Autopsy results were similar to those observed in untreated control 
mice which succumbed in our holding rooms during the same period of time. 
These  findings  show that  preparation  of BM  recipients  with  TLI  allows for 
engraftment without GVHD in a strain combination which shows severe GVHD 
when WBI is used for preparation. 
Although the mechanism by which TLI protects against GVHD remains to be 
elucidated,  the  severe  GVHD induced  by 30  x  106  allogeneic  spleen  cells in 
recipients  given TLI suggests that  the usual target organs are susceptible to 
immunological attack by mature immunocompetent T cells. Protection against 
GVHD by allogeneic BM cells may be due in part to the lack of development of 
mature  T  cells  and/or  to  the  development of suppressor cells from  immature 
cells  in  the  BM.  Even  susceptibility  to  GVHD  induced  by spleen  cells  was 
transient  in  mice  given  TLI,  since  no  GVHD  was  observed  after  multiple S.  SLAVIN,  Z.  FUKS,  H.  S.  KAPLAN,  AND  S.  STROBER  971 
injections of spleen cells into  stable chimeras  or into mice allowed to sponta- 
neously recover from TLI for a period of >100 days. It is likely that the aUogeneic 
spleen cells can only proliferate rapidly in the lymphoid tissues before repopu- 
lation by either progeny of the allogeneic BM cells, or that of the host's own BM 
cells. 
One important problem in clinical BM transplantation  is presensitization by 
blood transfusions  (1).  To  investigate  this  point  in  our  experimental  model, 
several  BALB/c mice  were given  0.25-ml  blood transfusions  from  C57BL/Ka 
donors on two separate occasions before the initiation of radiotherapy and BM 
transplantation.  The  experimental  results  show  that  the  blood transfusions 
prevented long-term engraftment of BM in recipients given TLI. This suggests 
that TLI cannot abrogate immunity to allogeneic BM cells induced by the blood 
elements. Further studies on the effects of TLI on the rejection of skin allografts 
in presensitized mice showed that TLI substantially prolongs allograft survival, 
even  in  mice  that  had  previously  rejected  a  skin  allograft.  However,  the 
survival time  (mean,  23 days) was less than  half of that in unsensitized mice 
given TLI (mean,  49.1 days). 
In  conclusion,  this  work  suggests  that  TLI  may be  a  useful  procedure  in 
clinical BM and organ transplantation.  TLI has already been used extensively 
in humans for treatment of lymphoid malignancies, and is a relatively safe form 
of radiotherapy  (10). 
Summary 
Bone  marrow  (BM)  and  skin  allografts  from  C57BL/Ka  (H-2  b/b) mice  were 
transplanted to BALB/c (H-2  d~d) recipients treated with total lymphoid irradia- 
tion  (TLI),  whole-body irradiation  (WBI),  or fractionated  thymic  irradiation. 
TLI  prolonged  skin  allograft  survival  about  five  times  as  long  as  that  in 
untreated  controls,  and  allowed  for  permanent  engraftment  of BM  cells  in 
---90% of recipients.  None of the BM recipients  showed clinical  signs of graft- 
versus-host disease (GVHD) (diarrhea,  weight loss, hunched back, etc.). On the 
other  hand,  recipients  given  WBI  and  allogeneic  BM cells  developed severe 
clinical  GVHD. The majority of the latter recipients died within  12 days after 
BM  transplantation,  and  95%  died  within  61  days.  Although  TLI  protected 
BALB/c mice against GVHD induced by BM cells, all recipients given TLI and 
allogeneic  spleen  cells  developed  lethal  GVHD.  Thymic  irradiation  alone 
marginally  prolonged skin allograft survival,  and did not allow for allogeneic 
BM engraftment.  These results suggest that TLI may be a  useful regimen in 
clinical BM transplantation,  since this form of radiotherapy is used extensively 
in humans and has few severe side effects. 
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